FIELD: medicine; pharmacology; infectious diseases.
SUBSTANCE: compound of formula I and a pharmaceutical composition based on it for the treatment of tuberculosis or Mycobacterium tuberculosis infection are proposed.
EFFECT: inventions provide new agents with unique mechanisms of action for the treatment of Mycobacterium tuberculosis infection.
13 cl, 2 tbl
Title | Year | Author | Number |
---|---|---|---|
PYRROLOPYRIMIDINE COMPOUNDS FOR MALIGNANT TUMOUR TREATMENT | 2012 |
|
RU2631655C2 |
PROTEOLYSIS MODULATORS AND RELATED USES | 2019 |
|
RU2805511C2 |
TETRAHYDROTRIAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF HUMAN NEUTROPHIL ELASTASE | 2012 |
|
RU2622643C2 |
BORON-CONTAINING SMALL MOLECULES AS ANTI-INFLAMMATORY AGENTS | 2009 |
|
RU2547441C2 |
FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | 2014 |
|
RU2679914C9 |
SUBSTITUTED 2H-PYRAZOLE DERIVATIVE | 2016 |
|
RU2722363C2 |
AZAINDAZOLE OR DIAZAINDAZOLE DERIVATIVES AS MEDICINE | 2012 |
|
RU2600976C2 |
PYRIDOPYRIMIDINE COMPOUND, METHOD FOR PRODUCTION, PHARMACEUTICAL COMPOSITION AND APPLICATION OF INDICATED COMPOUNDS | 2014 |
|
RU2662713C2 |
DERIVATIVES OF SUBSTITUTED PYRROLOPYRIDINONE USEFUL AS PHOSPHODIESTERASE INHIBITORS | 2001 |
|
RU2267490C2 |
NOVEL PYRAZOLE PYRIMIDINE DERIVATIVES | 2017 |
|
RU2769448C2 |
Authors
Dates
2023-09-07—Published
2018-07-17—Filed